A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of ...
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...
The number of U.S. children who suffer seizures after swallowing prescription medications or illicit drugs has doubled in ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
The CHMP also concluded that, after 18 months of treatment, the benefit seen with Leqembi on CDR-SB – a 1.21-point increase with the drug versus a 1.66-point rise with placebo – represented a ...
Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than in the US.
LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with An Alzheimer's drug in injectable form could be the key for Biogen, Eisai to ease pressures and concerns of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback